Schmitt G J E, Meisenzahl E M, Frodl T, La Fougère C, Hahn K, Möller H-J, Dresel S
Department of Psychiatry, Ludwig-Maximilians-University Munich, Munich, Germany.
J Psychopharmacol. 2005 Sep;19(5):488-93. doi: 10.1177/0269881105056530.
Following the current hypothesis that acute schizophrenic psychotic illness is associated with a striatal 'hyperdopaminergic state', presynaptic integrity and dopamine transporter (DAT) density in first-episode, neuroleptic-naive schizophrenic patients was measured by single-photon-emission-tomography (SPECT) and compared with that in healthy control subjects. A new SPECT-ligand for assessment of the striatal DAT, the Technetium-99m-labelled tropane TRODAT-1 ([99mTc]TRODAT-1), was used. Ten inpatients suffering from a first acute schizophrenic episode and 10 age- and sex-matched healthy control subjects underwent SPECT with [99mTc]TRODAT-1. On the day of SPECT, psychopathological ratings were performed with the Brief Psychiatric Rating Scale (BPRS), the Positive and Negative Syndrome Scale (PANSS) and Schedule for Assessment of Negative Symptoms (SANS). Patients had not previously received any neuroleptic or antidepressant medication. Mean specific TRODAT-1 binding in the striatum did not differ significantly between the patient and the age- and sex-matched control group (1.25 vs. 1.28). Variance was significantly higher in the patient group. The data obtained with the new ligand in first-episode, drug-naive schizophrenic patients are in line with the PET results from the group of Laakso et al. in a comparable patient sample. [99mTc]TRODAT-1 seems to be a valuable new SPECT-ligand in the evaluation of the presynaptic site of the striatal dopaminergic synapse in schizophrenia.
基于当前的假说，即急性精神分裂症性精神病与纹状体“多巴胺能亢进状态”相关，我们采用单光子发射断层扫描（SPECT）测量了首发、未使用过抗精神病药物的精神分裂症患者的突触前完整性和多巴胺转运体（DAT）密度，并与健康对照者进行比较。我们使用了一种用于评估纹状体DAT的新型SPECT配体，即锝-99m标记的托烷TRODAT-1（[99mTc]TRODAT-1）。10例首次急性精神分裂症发作的住院患者和10例年龄及性别匹配的健康对照者接受了[99mTc]TRODAT-1 SPECT检查。在SPECT检查当天，使用简明精神病评定量表（BPRS）、阳性和阴性症状量表（PANSS）以及阴性症状评定量表（SANS）进行精神病理学评分。患者此前未接受过任何抗精神病药物或抗抑郁药物治疗。患者组与年龄及性别匹配的对照组之间，纹状体中TRODAT-1的平均特异性结合无显著差异（分别为1.25和1.28）。患者组的方差显著更高。在首发、未使用过药物的精神分裂症患者中使用这种新型配体获得的数据与Laakso等人在类似患者样本中得到的PET结果一致。[99mTc]TRODAT-1似乎是评估精神分裂症纹状体多巴胺能突触前位点的一种有价值的新型SPECT配体。
